Skip to content

Stylized cells, blue

Category: Preclinical & Clinical

Cell and Gene Therapy at an Inflection Point: From Scientific Breakthrough to Sustainable Delivery

Part 31 of our Bridging the Gap Series (Summary of the webinar session held in June 2026) For much of the past two decades, the cell and gene therapy industry has been defined by scientific possibility. Researchers demonstrated that engineered cells could eliminate previously untreatable cancers. Gene therapies began addressing diseases once considered incurable. Manufacturing technologies evolved, […]

View Blog

Lessons from CTMC: Rethinking the Infrastructure Behind Cell Therapy Innovation

Part 30 of our Bridging the Gap Series (Summary of the webinar session held in May 2026) For all the momentum in cell and gene therapy, one challenge continues to define the field: how to move breakthrough science into patients faster, more efficiently, and at meaningful scale. Over the past decade, cell therapies have demonstrated extraordinary clinical […]

View Blog

Foundational Strategies That Can Shave Months Off Your Clinical Program: Biorepositories

Part 2 of our Strategies to Speed Clinical Trials Series The path from therapeutic discovery to regulatory approval remains long, with significant time devoted to clinical testing. When investing up to 15 years or more in a potential therapeutic, with much of that time dedicated to clinical trials1, any opportunity to save time during clinical phases can […]

View Blog

Building Cell Therapy at Scale: Saudi Arabia’s Vision for a Sustainable Advanced Therapies Ecosystem

Part 29 of our Bridging the Gap Series (Summary of the webinar session held in April 2026) For all the scientific progress in cell and gene therapy, one of the field’s biggest challenges remains the same: how to turn innovation into sustainable patient access. That question is especially important in regions where healthcare systems are growing quickly, […]

View Blog

Foundational Strategies That Can Shave Months Off Your Clinical Program: Biopharma

Part 1 of our Strategies to Speed Clinical Trials Series In the ever-competitive drug development landscape, time is a precious and limited resource. During often-complex clinical trials, every delay can have a real-world impact on patients, healthcare systems, and the bottom line. In fact, one recent review determined that reducing clinical development time from 10 months to […]

View Blog

Beyond Breakthroughs: Expanding Access to CAR-T Through New Manufacturing Models

Part 28 of our Bridging the Gap Series (Summary of the webinar session held in March 2026) For all the progress in cell and gene therapy, getting these treatments to patients remains one of the field’s greatest challenges. Today, only a fraction of eligible patients are able to access these therapies—often due not to science, but to […]

View Blog

CAR-T Beyond Blood Cancers: Re-engineering Cell Therapy for Solid Tumors

Part 27 of our Bridging the Gap Series (Summary of the webinar session held in February 2026) CAR-T therapy has already demonstrated what’s possible in certain blood cancers. However, solid tumors are proving much harder to treat. This challenge was the focus of Azenta’s recent Bridging the Gap webinar. Moderated by Olga Bukatova, Associate Director of Business […]

View Blog

Made-in-Canada CAR-T: How Collaboration Is Expanding Access to Cell Therapy

Part 26 of our Bridging the Gap Series (Summary of the webinar session held in January 2026) Cell and gene therapy is changing what’s possible for patients, particularly through CAR-T therapies for certain cancers. But access isn’t equal. Who receive treatment—and when—often comes down to geography, manufacturing capacity, cost, and infrastructure. Recently, leaders from Canada’s cell therapy […]

View Blog

From Lab to Landmark: What Europe’s First Nonprofit Gene Therapy Approval Means for the CGT Community

Part 25 of our Bridging the Gap Series (Summary of the webinar session held in December 2025) Editor’s note: Since this webinar, Waskyra has also received approval from the U.S. Food and Drug Administration (FDA), expanding access beyond Europe. One of the hardest challenges in cell & gene therapy (CGT) is determining how programs for ultra-rare diseases […]

View Blog

From Discovery to Delivery: Building Smarter Regulatory Pathways for Cell and Gene Therapy

Part 24 of our Bridging the Gap Series (Summary of the webinar session held in November 2025) Access to life-saving cell and gene therapies depends not only on scientific breakthroughs but also on the systems that bring those breakthroughs to patients. Regulations, infrastructure, and collaboration across borders determine whether a therapy moves from the lab to the […]

View Blog